Report Sellers has added a new market research report “Global Biosimilar Market” to its offerings. The report is an in-depth market study providing accurate market insights including the latest trends, forecast, competitive insights, etc.
Biosimilars are biopharmaceutical drugs that are highly similar to already approved biological product (also known as biological reference product). Biosimilars are unique and can never be identical to the reference product as these are grown in living cells. Biosimilars are not generics but have close proximity to generic version of various biologics. The emergence of biologics had already revolutionized treatment options for the large variety of diseases. There is increased market opportunity for biosimilars with the majority of biologics losing exclusivity in upcoming years. Biosimilars have substantial potential to increase access to biological therapies while enhancing the cost-effectiveness of healthcare systems globally.
Growing demand for biosimilars and biologics worldwide is demonstrated by the magnitude of biological patent expiries, cost savings associated with the use of biosimilars and increased use of biosimilars for treatment of chronic diseases. Major market restraints biosimilars market are the high cost of development of biosimilars, regulatory uncertainty, the lower adoption rate of biosimilars and manufacturer skill gap. Some of the leading industry trends and developments include new biosimilar products dominated by Large Globals, increased focus on pharmerging markets and issuance of much-awaited biosimilar interchangeability guidance by FDA.
The report provides information on the current scenario, the detailed market outlook of the global biosimilar market. Detailed analysis of Biosimilar market segmentation by application area Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) has been covered in the report. Future forecasts of major segments, as well as biosimilar markets in developed and emerging nations till 2020, is provided in the report. Furthermore, key industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the market include Biocad, TEVA, Celltrion, Sandoz, Dong-A Pharmaceutical Co., Ltd., Hospira, Intas, Stada Arzneimittel, among others. Sandoz, Hospira, TEVA, Celltrion, Biocad and Dong-A Pharmaceutical Co., Ltd. are profiled herein based on attributes such as business overview, product pipeline, financial and business strategies. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global biosimilars market in both developed and emerging economies.
Browse through the complete description and in-depth TOC on “Global Biosimilar Market”
Sandoz, Hospira, TEVA, Celltrion, Biocad and Dong-A Pharmaceutical Co., Ltd.
Global, Europe, the US, China, India
We have a large number of reports in other Pharmaceuticals Industry which can be accessed in the following link:
Report Sellers is a premium market research service provider offering market reports in varied sectors. We have a team of experienced analysts and publishers who continuously track the latest trends in different industries.
Report Sellers is a brand of global repute and offers the best-suited research services to its clients globally in the most satisfying manner. We have a strong network of industry experts who have successfully delivered complex research assignments in niche and top markets.
For more information, contact